Luye Builds China Cancer Diagnosis Capability Via Vela Investment
This article was originally published in PharmAsia News
Executive Summary
As a Chinese healthcare player investing money into the oncology treatment market, Luye Group is seeking to stay ahead of the competition by adding disease screening and in vitro diagnostics to its arsenal, via a major investment into Vela Diagnostics of Singapore. As the window of opportunity closes in, the two are working quickly to bring products to the China market.
You may also be interested in...
Luye Looks To Horizons Beyond Pharma, China
Dianbo Liu, chairman of the Hong Kong listed Luye Group, talks about the company’s ambitious plans to become a global top 100 pharmaceutical company through innovation, acquisitions and overseas expansion, and to broaden its activities well beyond selling medicines to meet changing patient needs and industry pressures.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.